Grant: Fellowship - PA: CIHR/Rx&D - CAMO Research Program
University of Ottawa
$35,000.00
Preclinical/clinical evaluation of a CDK4/6 inhibitor + 5-FU in colon cancer
EF 2008-09
Résumé
5-Fluorouracil (5-FU) is a commonly used chemotherapy in Breast and Colon cancer. Unfortunately, it often stops working with time because cancer cells mutate and change the target for 5-FU. We are currently working with a new drug that helps undo this mutated change and enables 5-FU to have its continued effect on cancer cells. Tests completed on cancer cells grown in the labratory are encouraging and we hope to initiate a clinical trial evaluating the combination soon. If the combination of this new drug and 5-FU is effective, many canadians with Breast & Colon cancer could expect longer responses to 5-FU chemotherapy and potentially longer survival.
Programme
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
178342
Name
Vickers Michael M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Medical Oncologists (Ottawa)
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Preclinical/clinical evaluation of a CDK4/6 inhibitor + 5-FU in colon cancer
Programtype2
Fellowship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$35,000
Cihrequipment2
$0
Programname2
Fellowship - PA: CIHR/Rx&D - CAMO Research Program
Keyworddelim
Human Cancer Cell Lines; Medical Oncology; Novel Chemotherapy Agent; Overcoming Chemotherapy Resistance; Phase I Clinical Trial
Abstract
5-Fluorouracil (5-FU) is a commonly used chemotherapy in Breast and Colon cancer. Unfortunately, it often stops working with time because cancer cells mutate and change the target for 5-FU. We are currently working with a new drug that helps undo this mutated change and enables 5-FU to have its continued effect on cancer cells. Tests completed on cancer cells grown in the labratory are encouraging and we hope to initiate a clinical trial evaluating the combination soon. If the combination of this new drug and 5-FU is effective, many canadians with Breast & Colon cancer could expect longer responses to 5-FU chemotherapy and potentially longer survival.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vickers, Michael M
Approvedterm
1 an 0 mois
Cihrcontribution2
Patient Oriented Research~ $35,000~ $0~